Clinical Trials
19 trialsNCT04660929 2024-12-18
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
Phase 1 Unknown
NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Unknown
NCT05311618 2024-04-01
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Unknown
NCT05872867 2024-03-12
MK-3475-E90
Wellmarker Bio
Phase 1 Unknown
NCT06307093 2024-03-12
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
Phase 1 Unknown
NCT04224480 2024-01-19
Longitudinal Immune-phenotyping of HCC Following MK-3475
National Cancer Centre, Singapore
Phase 1 Unknown
NCT04294576 2023-11-09
FIH
BJ Bioscience, Inc.
Phase 1 Unknown
NCT05296772 2023-09-06
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Phase 1 Unknown
NCT05739006 2023-08-02
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
Biocad
Phase 1 Unknown
NCT05232409 2023-04-20
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Valley Health System
Phase 1 Unknown
NCT05700955 2023-01-26
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
Phase 1 Unknown
NCT04460456 2022-06-30
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
Phase 1 Unknown
NCT03626922 2022-06-10
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
NSABP Foundation Inc
Phase 1 Unknown
NCT02675946 2022-01-26
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
Phase 1 Unknown
NCT04859777 2021-09-16
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Monopteros Therapeutics Inc.
Phase 1 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT02824965 2021-07-07
Pembrolizumab + CVA21 in Advanced NSCLC
Olivia Newton-John Cancer Research Institute
Phase 1 Unknown
NCT04866485 2021-04-29
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
Harbour BioMed (Guangzhou) Co. Ltd.
Phase 1 Unknown
NCT03396497 2019-09-25
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Lycera Corp.
Phase 1 Unknown